secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2026-03-20T23:59:59+00:00
Accession:  0001193125-26-117765
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics reprices stock options to $3.91; original exercise price applies if exercised before Premium End Date
--------------------------------------------------------------------------------

- Board approved repricing of all outstanding options to $3.91 per share (closing price on March 19, 2026).
- Repriced options subject to original exercise price if exercised before Premium End Date (Sept 19, 2027, change in control, or death/disability).
- Named executive officers hold 1,106,764 total Eligible Options with original exercise prices ranging from $6.60 to $17.88.
- CEO Eric Easom holds 742,649 repriced options; CFO Lucy Day holds 221,965; CLO/COO Joshua Eizen holds 142,150.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312526117765/0001193125-26-117765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312526117765/d107794d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-117765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer